Osiris shares up as FDA clears reimbursement pathway for wound treatment

(Reuters) - Shares of Osiris Therapeutics Inc rose as much as 15 percent on Wednesday, after the stem-cell technology company's wound treatment received a temporary reimbursement code from U.S. health regulators. The U.S. Food and Drug Adminis...

Source: http://health.yahoo.net/news/s/nm/osiris-shares-up-as-fda-clears-reimbursement-pathway-for-wound-treatment

Jesus Receipt design John Edwards Jorja Fox